Company Overview of Moderna Therapeutics, Inc.
Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc.; and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck. The company was incorporated in 2009 and i...
200 Tech Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Moderna Therapeutics, Inc.
Founding Chief Executive Officer and Director
Co-Founder, Chairman and Member of Technology Advisory Board
President of Research and Development
Compensation as of Fiscal Year 2016.
Moderna Therapeutics, Inc. Key Developments
Moderna Therapeutics to Build Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Massachusetts
Sep 21 16
Moderna Therapeutics announced that it has signed a long-term lease (15 years plus renewal options) to build a Good Manufacturing Practices (GMP) clinical manufacturing facility in Norwood, Massachusetts. Moderna is committed to developing a broad array of medicines leveraging its leading mRNA platform, and to delivering on the promise of mRNA science for patients as quickly as possible. To support and manage this anticipated breadth of clinical studies, Moderna’s 200,000 square foot Norwood facility will enable the manufacture, quality, control and supply of clinical grade mRNA therapies and vaccines for Good Laboratory Practices (GLP) toxicology studies as well as Phase 1 and Phase 2 clinical studies. At the site, Moderna will carry out all manufacturing activities "from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish. Moderna will begin initial build-out of the new facility in October 2016. The company plans to open the facility by early 2018.
Moderna Therapeutics Appoints Melissa J. Moore as Chief Scientific Officer of its mRNA Research Platform, Effective October 3, 2016
Sep 13 16
Moderna Therapeutics announced that Melissa J. Moore, Ph.D., has been appointed Chief Scientific Officer (CSO) of Moderna’s mRNA research platform. Responsible for leading all mRNA biology research at Moderna, Dr. Moore will play a critical leadership role as the company enters a new growth phase, and will help guide Moderna towards its vision of delivering on the promise of mRNA science for patients. Dr. Moore will assume her new role at Moderna as of October 3, 2016. Currently a member of Moderna’s Scientific Advisory Board, Dr. Moore joins the company from the University of Massachusetts Medical School (UMMS), where she is currently Professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research and Investigator at the Howard Hughes Medical Institute (HHMI). In addition, Dr. Moore was a founding Co-Director of the RNA Therapeutics Institute (RTI) at UMMS. Upon joining Moderna, Dr. Moore will resign from HHMI, but retain her academic affiliation with UMMS as a part-time faculty member.
Moderna Therapeutics, Inc. Presents at The 23rd Annual NewsMakers in the Biotech Industry Conference, Sep-09-2016
Aug 16 16
Moderna Therapeutics, Inc. Presents at The 23rd Annual NewsMakers in the Biotech Industry Conference, Sep-09-2016. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Presentation Date(s): Sep-09-2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 10, 2016
July 6, 2016
October 22, 2015